F Cappuzzo et al Increased
 F. Cappuzzo, et al., Increased MET gene copy number negatively aﬀects survival of surgically resected non-small-cell lung cancer patients, J. Clin. Oncol. 27 (10) (2009) 1667–1674.
 H. Yoshioka, et al., A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-MET inhibitor tivantinib (ARQ 197) in Asian pa-tients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (attention study), Ann. Oncol. 26 (10) (2015) 2066–2072.
 G. Scagliotti, et al., Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, J. Clin. Oncol. 33 (24) (2015) 2667–2674.
 D.R. Spigel, et al., Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: metlung, J. Clin. Oncol. 35 (4) (2017) 412–420.
 A. Li, et al., Predictive and prognostic value of de novo MET G418 in patients with advanced non-small-cell lung cancer, Lung Cancer 90 (3) (2015) 375–380.  J.Y. Kang, et al., Tissue microarray analysis of hepatocyte growth factor/MET pathway components reveals a role for MET, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer, Cancer Res. 63 (5) (2003) 1101–1105.
 M.P. Barr, et al., Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature, PLoS One 8 (1) (2013) e54193.
 F.A. Shepherd, et al., Pooled analysis of the prognostic and predictive eﬀects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage re-sected non-small-cell lung cancer in four trials of adjuvant chemotherapy, J. Clin. Oncol. 35 (18) (2017) 2018–2027.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/canlet
C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
Tae-Min Choa,b,1, Ji Young Kima,1, Yoon-Jae Kima,c, Daeil Sunga,b, Eunhye Oha,b, Seojin Janga,b, Lee Farrandd, Van-Hai Hoange, Cong-Truong Nguyene, Jihyae Anne, Jeewoo Leee,∗∗, Jae Hong Seoa,b,∗ a Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul, 152-703, Republic of Korea b Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Korea University, Seoul, 152-703, Republic of Korea c Department of Biomedical Research Center, Korea University Guro Hospital, Korea University, Seoul, 08308, Republic of Korea d AusHealth Research, 65 Hardys Rd, Underdale, Adelaide, South Australia, 5032, Australia e Laboratory of Medicinal Chemistry, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea
C-terminal HSP90 inhibitor
Triple-negative breast cancer
Cancer stem cells
Triple-negative breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile. It has an earlier tendency to form metastases and is associated with poor clinical outcomes due to the limited treatment options available. Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins. We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis. L80 suppressed cell viability and concomitantly in-hibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells. L80 effectively targeted BCSC-like traits, together with significant reductions in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability. In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo. These phenomena were associated with the suppression of BCSC-like characteristics and STAT3 dysfunction. Our findings highlight properties of the L80 compound that may be useful in suppressing metastatic TNBC.